retatrutide ly3437943 parkinson's disease clinical trial (LY3437943), a Novel GIP/GLP-1/Glucagon Receptor Triagonist—Obesity, NAFLD, and T2D Phase 2 Results Retatrutide Meets Phase 3 Weight-Loss

Are other medications contributing

In a separate study , published in JAMA in August 2025, the same researchers found that, across ages, GLP-1s were associated with lower risk of some obesity-related cancers, such as endometrial, ovarian, and meningioma cancers, but with an increased risk of kidney cancer, and nonsignificant changes for several other cancers

Not everyone who uses a GLP-1 will benefit from or be successful with the therapy, so covering GLP-1s across the board is too costly and would mean higher premiums for everyone

Medication and supplement list reviewed with care team Post-op wound care, nutrition, hydration, and light activity

Best blood test for: Quick checks: Core Health Blood Test Weight loss checks: Weight Loss Blood Test In-depth checks: Advanced Well Woman Blood Test or Advanced Well Man Blood Test GLP-1 injection checks: Weight Loss Injection (GLP-1) Monitoring Blood Test References Geng J, Ni Q, Sun W, Li L, Feng X